image credit: Adobe Stock

Junshi Biosciences, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia

March 30, 2023

Junshi Biosciences Co., Ltd and Rxilient Biotech entered into a collaboration for the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab, through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.

“This extensive collaboration with Rxilient Biotech in Southeast Asia is a vital step for Junshi Biosciences as we strive to expand our global commercialization network,” said Ning LI, CEO of Junshi Biosciences. “Southeast Asia boasts a thriving pharmaceutical innovation environment, flexible drug regulatory policies, and diversified medical security systems, so it has great potential as an emerging market for innovative drugs.”

Read More on Contract Pharma